MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Akciju saraksts・Cumberland Pharmaceuticals Inc

C
Cumberland Pharmaceuticals Inc

Atvērts

4.18 -10.3

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.16

Max

4.68

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.2M -1.9M
Pārdošana	-2.5M 8.3M
Peļņas marža	-23.404
Darbinieki	91
EBITDA	-1.2M -796K

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 3. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	28M 70M
Iepriekšējā atvēršanas cena	14.48
Iepriekšējā slēgšanas cena	4.18

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

4.325 / 4.845 Atbalsts un pretestība

Cumberland Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. janv. 23:49 UTC

Galvenie tirgus virzītāji

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026. g. 21. janv. 21:12 UTC

Galvenie tirgus virzītāji

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 21:00 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026. g. 21. janv. 20:29 UTC

Galvenie tirgus virzītāji

Chip Makers Gain After Trump Calls Off European Tariffs

2026. g. 21. janv. 20:04 UTC

Galvenie tirgus virzītāji

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026. g. 21. janv. 23:34 UTC

Tirgus saruna

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026. g. 21. janv. 22:39 UTC

Peļņas

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 21. janv. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026. g. 21. janv. 21:19 UTC

Peļņas

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026. g. 21. janv. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026. g. 21. janv. 20:36 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026. g. 21. janv. 20:31 UTC

Tirgus saruna

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026. g. 21. janv. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Was It a 'TACO' Event? -- Market Talk

2026. g. 21. janv. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026. g. 21. janv. 20:23 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026. g. 21. janv. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026. g. 21. janv. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Group Agrees to Buy Allfunds

2026. g. 21. janv. 20:08 UTC

Peļņas

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026. g. 21. janv. 20:03 UTC

Tirgus saruna

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026. g. 21. janv. 19:51 UTC

Tirgus saruna

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026. g. 21. janv. 19:43 UTC

Tirgus saruna

U.S. Ethanol Production Expected to Slip -- Market Talk

2026. g. 21. janv. 19:31 UTC

Tirgus saruna

Gold Settles at Fresh All-Time High -- Market Talk

2026. g. 21. janv. 19:24 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026. g. 21. janv. 19:10 UTC

Tirgus saruna

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026. g. 21. janv. 18:57 UTC

Tirgus saruna

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cumberland Pharmaceuticals Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cumberland Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.325 / 4.845Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.